Half Beta-Prograne

Quick links to important sections

Half Beta-Prograne

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Half Beta-Prograne

Here is a structured overview of the medicine, Half Beta-Prograne, establishing its identity, composition, and general purpose without discussing usage instructions or safety information.

Property Description
Active Ingredient Propranolol Hydrochloride
Form Prolonged-Release Capsule (Sustained Release)
Pharmacological Class Non-selective Beta-Adrenergic Antagonist (Beta-blocker)
General Purpose Cardiovascular regulation and support
Origin Synthetic compound

Half Beta-Prograne is a synthetic, single-ingredient, prescription-only medication whose active component is Propranolol Hydrochloride. It is formally classified as a beta-adrenergic antagonist, commonly known as a beta-blocker. This classification means the medicine is designed to interfere with the action of adrenaline and noradrenaline at specific beta-receptors throughout the body.


What Type of Medicine is Half Beta-Prograne?

This medication is specifically identified as a non-selective beta-blocker, a characteristic that means it affects both beta1 receptors (primarily related to the heart) and beta2 receptors (found in blood vessels and lungs). Furthermore, Propranolol exhibits a membrane stabilization effect (a quinidine-like action), which allows it to be categorized as a Group II antiarrhythmic agent. Its fundamental action lies in decreasing heart rate and force, a key property for managing conditions related to elevated cardiac workload.


Composition and Pharmaceutical Form of Half Beta-Prograne

The composition features Propranolol Hydrochloride as the sole active ingredient, delivered via oral administration in the form of a Prolonged-Release Capsule. This pharmaceutical design, often referred to as a Sustained Release Capsule, contains microgranules that control the rate at which the active substance is absorbed. This controlled release mechanism ensures that the therapeutic effect is maintained consistently over an extended period, which provides a key differentiating factor over immediate-release tablets.


General Physiological Purpose of a Beta-Blocker

The overall purpose of this type of medicine is to provide fundamental cardiovascular support by modulating the body's response to natural stress hormones. The medication acts to reduce the heart’s workload by slowing the rate and decreasing the force of its contractions. This general action promotes stabilization within the circulatory system, helping to ease strain on the heart muscle.

Regulatory References

  1. Group II Antiarrhythmics (NIH)
  2. Beta Blockers Pharmacology (NIH)
  3. NIH Group II Antiarrhythmics

What side effects are possible with Half Beta-Prograne?

The safety profile of Half Beta-Prograne (Propranolol Hydrochloride) is formally defined by its regulatory classification, outlining adverse reactions based on their frequency and the body system affected. This information is derived exclusively from official government labeling.

Documented Adverse Reactions and Frequencies

Adverse effects are categorized by frequency, reflecting how often they appeared in clinical data. Common reactions include bradycardia (slow heart rate), cold extremities, Raynaud's phenomenon, and general symptoms like fatigue and lassitude, which are often noted as transient. Effects on the nervous system, such as sleep disturbances and nightmares, are also classified as common.

Less frequent, Rare adverse reactions span multiple system-organ classes, including the nervous system (e.g., hallucinations, confusion, memory loss) and the cardiovascular system, where deterioration of heart failure and precipitation of heart block are officially documented. Gastrointestinal disturbances (nausea, vomiting, diarrhea) are typically categorized as uncommon.

Serious Safety Considerations and Special Populations

Serious adverse reactions officially documented include the potential for severe bronchospasm, especially in susceptible individuals, and acute, severe forms of hypoglycemia which can be masked by the medicine's effects. Safety constraints also note that the medicine is contraindicated in specific conditions like decompensated heart failure and certain types of heart block.

Official labeling includes considerations for special populations. In diabetic patients, the medication may mask the typical signs of acute hypoglycemia. For older adults and those with hepatic or renal impairment, altered drug clearance is noted in regulatory texts. A key duration-related safety pattern is the risk of exacerbation of angina or other serious cardiac events if therapy is abruptly discontinued.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Half Beta-Prograne (Propranolol Hydrochloride) is a severe medical emergency that requires immediate intervention. Official regulatory documents characterize the overdose profile primarily by profound cardiovascular depression resulting from excessive beta-blockade. Manifestations typically include severe bradycardia (abnormally slow heart rate), marked hypotension (dangerously low blood pressure), and disturbances in cardiac conduction. Life-threatening outcomes documented in the labeling include cardiogenic shock, cardiac arrest, and respiratory failure.

The official profile also details severe effects on the central nervous system, such as seizures (convulsions) and coma, along with the risk of hypoglycemia (low blood sugar), which can be profound and is a particular concern in pediatric patients. Due to the sustained-release nature of the capsule, toxicity may be delayed or prolonged, necessitating extended observation.

Because of the potential for rapid deterioration and severe outcomes, regulatory guidance explicitly states that if an overdose is suspected, you must seek immediate medical attention and contact emergency services immediately. Management is defined as symptomatic and supportive treatment, as there is no specific antidote known to reverse all effects. Hospital monitoring is required for adequate assessment and management.

Therapeutic Uses of Half Beta-Prograne

Main Uses and Benefits of Half Beta-Prograne

Half Beta-Prograne provides supportive relief for cardiovascular conditions by addressing symptoms related to heightened physiological activity, such as high systemic blood pressure (hypertension) and various cardiac arrhythmias that cause a rapid or irregular pulse. This supportive relief contributes to maintaining heart rhythm stability and helps to ease the overall workload on the heart. It is applied in clinical settings that involve management after a heart attack and for patients with chronic stable angina pectoris (chest pain with exertion). The primary therapeutic role is focused on these areas, alongside essential tremor and migraine prophylaxis.


It is generally used for managing symptoms related to increased neurological or muscular activity, such as involuntary shaking (tremor), and is used for managing recurrent migraine headaches. This assistance may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms. The medicine is also relevant for providing symptomatic support in conditions like thyrotoxicosis and for therapeutic assistance in proliferating infantile hemangioma.


Quick Fact: Relief for Physical Trembling

Half Beta-Prograne is commonly used to help with the symptomatic management of essential tremor, assisting with maintaining functional stability and providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who can and cannot use Half Beta-Prograne — Official Regulatory Information

Half Beta-Prograne is an extended-release medicine that is contraindicated (must not be used) in several specific populations, primarily those with severe cardiac or respiratory conditions. The primary contraindications include:

  • A history of bronchial asthma or bronchospasm.
  • Severe, uncontrolled heart rhythm or function issues, such as uncontrolled heart failure, cardiogenic shock, second or third degree heart block, sick sinus syndrome, or abnormally slow heart rate (bradycardia).
  • Very low blood pressure (hypotension).
  • Severe peripheral arterial circulatory disturbances, such as severe Raynaud's syndrome.
  • Untreated phaeochromocytoma or metabolic acidosis.
Population Group Eligibility Status (Regulatory Basis)
Children Not suitable for use (80 mg prolonged-release capsules).
Older Adults (Elderly) Use with caution; treatment should start at the lowest possible dose.
Pregnancy Use is restricted to when absolutely necessary.
Lactation Breastfeeding is not recommended as the medicine passes into breast milk.
Hepatic or Renal Impairment Requires caution; the initial dose must be low.
Diabetes Requires caution as it may mask the signs of low blood sugar (hypoglycemia).

In patients with a controlled heart condition, use may be allowed under strict medical supervision. Treatment must not be stopped suddenly in patients with ischaemic heart disease due to the risk of worsening symptoms.

What should I know about interactions with other medicines?

Half Beta-Prograne (which contains propranolol) can interact with a wide range of prescription and non-prescription medicines, as well as certain substances, potentially affecting how it or the other product works. It is essential to inform your healthcare provider about all medicines, herbal supplements, and dietary products you are currently taking.

Medications with Potential Interaction

Category Examples of Interacting Medicines Potential Effect
Other Heart/Blood Pressure Drugs Calcium channel blockers (e.g., verapamil, diltiazem), ACE inhibitors, other beta-blockers, digoxin May cause severely low blood pressure or heart rate
Heart Rhythm Regulators Amiodarone, propafenone, quinidine Increased risk of very slow heartbeat or other heart problems
Migraine Treatments Triptans (e.g., rizatriptan) Increased blood levels of both medicines
Antidepressants SSRIs (e.g., fluoxetine, fluvoxamine), tricyclic antidepressants Increased blood levels of Half Beta-Prograne
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Ibuprofen, indomethacin May reduce the blood pressure-lowering effect of Half Beta-Prograne
Antimicrobials Rifampicin, cimetidine Can change the concentration of Half Beta-Prograne in the blood
Antidiabetic Agents Insulin, oral hypoglycemics May mask the warning signs of low blood sugar (hypoglycemia)

Other Important Interactions

Alcohol consumption while taking this medicine is not recommended as it may increase the concentration of propranolol in the blood, leading to potential side effects like dizziness. If you are scheduled for surgery involving general anesthetics, you must inform the medical staff that you are taking this medicine, as anesthetics may interfere with its effects and cause low blood pressure.

Mechanism of Action

The action of Propranolol involves competitive interaction with adrenergic receptors. The mechanism focuses on biological targets to produce systemic physiological effects.

Modulating the Heart and Kidney's Sympathetic Signaling

This medicine acts as a non-selective competitive antagonist at both beta1 and beta2 adrenergic receptors. By blocking the beta1 receptors found predominantly in the heart, the drug directly reduces the binding affinity of epinephrine and norepinephrine, initiating a molecular cascade that decreases heart rate (negative chronotropy) and the force of contraction (negative inotropy). Simultaneously, beta1 receptor blockade on the renal cells suppresses the release of renin, which is a component of the Renin-Angiotensin-Aldosterone System (RAAS) pathway.

Non-Adrenergic and Central Pathway Influence

Beyond beta-receptor antagonism, the molecule possesses high lipophilicity, allowing it to cross into the Central Nervous System (CNS) where it can attenuate central sympathetic outflow. Furthermore, at higher concentrations, the drug exhibits a distinct membrane stabilization effect by blocking fast voltage-gated sodium ( Na^+) channels in the heart muscle. This action is separate from the primary beta-blockade and directly influences the electrical excitability of the cardiac cells. The non-selective blockade of beta2 receptors in the periphery also modulates vascular and bronchial smooth muscle tone.

Dosage and Administration Information

How to Use Half Beta-Prograne

Half Beta-Prograne (Propranolol Hydrochloride Prolonged-Release Capsules) is administered exclusively via the oral route and is designed for once daily (QD) dosing. The medicine is released over an extended period, which mandates that the capsule must be swallowed whole and must not be crushed, opened, or chewed to preserve its sustained-release action.


Official Dosing and Titration

Standard adult dosing involves starting with a low initial dose, followed by a process of titration, or gradual adjustment. For indications like high blood pressure (hypertension) or angina pectoris, the usual starting dose is often 80 mg or 160 mg once daily. Doses are typically increased in increments of 80 mg over intervals of several days or weeks until the desired maintenance dose is achieved. Depending on the indication, the maximum recommended daily dose may be up to 320 mg.


Administration Conditions and Special Populations

Administration is generally consistent; the capsule is taken once daily, either in the morning or evening, and some formulations direct use at bedtime, consistently taken either with or without food.

Specific usage rules apply for certain populations. For older adults and patients with known hepatic or renal impairment, treatment initiation requires extra caution, starting with the lowest available dose. Furthermore, these high-strength prolonged-release capsules are not intended for use in children. If treatment is to be discontinued, the dosage must be reduced gradually over a period of a few weeks, as abrupt cessation is discouraged.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Half Beta-Prograne

Evidence for Use in Essential Tremor (ET)

Half Beta-Prograne was studied for the management of symptoms in individuals with Essential Tremor. The research largely involved short-term Randomized Controlled Trials (RCTs) used in research exploring how symptoms change over time, focusing on measuring tremor severity scores and functional measures. Findings describe patterns observed in the studies over short periods. However, findings were mixed across trials, and data show patterns related to various factors that indicate the observed patterns may vary between individuals.

Evidence for Use in Migraine Prophylaxis (MP)

For the management of migraine, Half Beta-Prograne was observed in multiple placebo-controlled RCTs. These trials monitored outcomes describing episodic or acute changes, specifically evaluating measurements of migraine day frequency and acute medication use. The research highlights changes measured during the study period over defined time intervals of 8 to 16 weeks.

Long-Term Studies and Follow-up Data

Research examined the patterns of the agent through extension studies and observational settings. While these studies allow for monitoring and evidence suggests patterns of stability, long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of the observed changes after the initial treatment period.

What is Still Uncertain About Half Beta-Prograne Research

Despite the existing body of work, data for certain groups remain insufficient. Specifically, few data are available for pediatric populations across all indications. Follow-up durations were limited in the core efficacy trials, and subgroup findings are uncertain for the most severe forms of conditions or for patients with multiple complex medical issues. Research is ongoing to address some of these evidence gaps.

Frequently Asked Questions (FAQ)

Common questions about Half Beta-Prograne (FAQ)


Q: What is the main reason doctors prescribe Half Beta-Prograne?

Official product information states that Half Beta-Prograne is indicated for several conditions. These include managing hypertension (high blood pressure), angina pectoris (chest pain), specific types of irregular heart rhythms, and for the prevention of migraine headaches and essential tremor.


Q: How quickly should I feel the effects of Half Beta-Prograne?

The medicine is designed as a prolonged-release capsule, meaning the active substance is released slowly over time. Regulatory pharmacokinetic data show that the concentration typically peaks in the bloodstream approximately 6 hours after administration. However, the time it takes to observe the full physiological effect may vary between individuals.


Q: Does Half Beta-Prograne cause weight gain?

Weight gain is not consistently listed as a common adverse reaction in official regulatory labeling. While some case reports and observations have been noted, weight gain is not formally defined as a frequent side effect in the primary regulatory product information.


Q: Can I take Half Beta-Prograne if I drink coffee?

Official drug interaction databases generally do not list a direct interaction between the active ingredient and caffeine. However, because caffeine can stimulate the heart, it may counteract some of the drug's intended effects. It is important that any use with caffeine is done in consultation with a health care provider.


Q: What happens if a dose of Half Beta-Prograne is missed?

Official patient information describes that if a dose is missed, the medicine should be taken as soon as it is remembered. If it is nearly time for the next scheduled dose, you should skip the missed dose and resume your regular schedule. It is important that you do not take a double dose to make up for the one you missed.


Q: Can Half Beta-Prograne be used for anxiety or performance stress?

Regulatory documents list the approved indications for Half Beta-Prograne as certain cardiovascular and neurological conditions, such as hypertension, angina, and essential tremor. The official labeling confines its approved use to the listed cardiovascular and neurological indications.


Q: Can Half Beta-Prograne cause changes in mood?

Yes, official regulatory documents list adverse reactions that involve changes to mental state. These can include feelings of mental depression, episodes of confusion, and in rare cases, hallucinations.


Q: Are there different strengths of Half Beta-Prograne available?

Yes, the official prescribing information states that the prolonged-release capsules of the active ingredient are available in multiple strengths. These typically include 60 mg, 80 mg, 120 mg, and 160 mg for oral administration.


Q: Is Half Beta-Prograne described as being a common treatment for high blood pressure?

The medicine is formally indicated for the management of hypertension (high blood pressure) as a non-selective beta-adrenergic receptor blocker. Its classification indicates a role in cardiovascular regulation and the management of high blood pressure.


Q: Can this medication affect athletic performance?

As a beta-blocker, this medicine acts to reduce the heart rate and the volume of blood the heart pumps (cardiac output). This physiological change may influence physical capacity and endurance, particularly during strenuous exercise.


Q: Are there generic versions of Half Beta-Prograne available?

Official drug registries show that the active ingredient, Propranolol Hydrochloride prolonged-release capsules, is widely available under its generic name.


Q: Is it possible to be allergic to Half Beta-Prograne?

Yes, official labeling states that the medicine is contraindicated (must not be used) in patients with a known hypersensitivity to the active ingredient. Additionally, allergic reactions or hypersensitivity reactions are listed as potential adverse reactions in the official safety information.


Q: Why is monitoring necessary when starting Half Beta-Prograne?

Monitoring is necessary, especially during the titration phase when the dose is being gradually adjusted. This is done to ensure the medicine is achieving its desired therapeutic effect and to check for potential adverse effects, such as excessively slow heart rate or low blood pressure, which may require dose adjustment.


Q: Can Half Beta-Prograne affect my ability to drive or operate machinery?

Official product information advises that the medicine is generally considered unlikely to significantly impair driving ability. However, because it can occasionally cause side effects like dizziness or fatigue, regulatory guidance states that caution is advised until an individual knows how the medicine affects them.


Q: Are skin rashes a reported side effect of Half Beta-Prograne?

Yes, regulatory documents list skin rashes as reported adverse reactions. These can include types such as erythematous rash (redness) and urticaria (hives), as well as rare, severe dermatological reactions.


Q: How does Half Beta-Prograne compare to other beta-blockers in terms of side effects?

This medicine is classified as a non-selective beta-blocker, meaning it affects both beta-1 and beta-2 receptors in the body. Due to this non-selective action, effects such as bronchospasm and cold extremities are noted in official information, a pattern that may differ from highly selective beta-blockers.


Q: Is there a patient leaflet available for Half Beta-Prograne online?

Yes, regulatory agencies and government databases, such as DailyMed, provide the official Patient Information Leaflet (PIL) or Medication Guide for the active ingredient. These documents contain detailed information reviewed by regulatory authorities.


Q: What are the common reasons a doctor might choose Half Beta-Prograne over other options?

The choice may relate to the drug's specific characteristics, such as its ability to affect the central nervous system and its non-selective action, making it suitable for certain indications like essential tremor and migraine prophylaxis.


Q: Can Half Beta-Prograne make you feel tired or dizzy?

Official adverse reaction reports list fatigue and lassitude (tiredness) as common side effects. While dizziness is not listed as common, regulatory information states that caution is advised, as this is a recognized potential effect that can be exacerbated by certain interactions, such as alcohol.


Q: Are there any common foods or drinks that interact with Half Beta-Prograne?

The official interaction documents only specifically advise against the use of alcohol due to its potential to increase the drug's concentration in the blood. Otherwise, no specific dietary restrictions are typically noted in official documents, other than the guidance regarding alcohol.


Q: Is Half Beta-Prograne safe for older adults?

Official guidance indicates that older adults require specific consideration. Treatment for this population should be initiated with the lowest available dose. This is due to a recognition of potential differences in how the drug is cleared by the body in older patients.


Q: What is the longest period a person has been studied taking Half Beta-Prograne?

While definitive long-term outcomes are not fully established, official research summaries confirm that extension studies and observational settings have been used for monitoring patterns of long-term use.


Q: Does Half Beta-Prograne interact with cold and flu remedies?

Interactions are formally documented with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen, which are common in cold remedies. It is important that any use of over-the-counter medicines is reviewed with a healthcare provider, as other components like decongestants can potentially interact.


Q: Can I take multivitamins or supplements while using Half Beta-Prograne?

Official drug information lists a general caution about potential interactions with herbal supplements and certain dietary products. It is important that a healthcare provider is informed about all non-prescription products, including vitamins and supplements, to screen for any potential issues.


Q: What is the difference in how Half Beta-Prograne is used for heart versus nerve conditions?

The medicine is effective for both cardiovascular and neurological conditions due to its non-selective action and ability to affect the central nervous system. While dosing must always be individualized, the target dosage ranges or the time required to see a full effect may differ significantly between conditions like hypertension and essential tremor.


Q: Does research show a difference in outcomes for different age groups using Half Beta-Prograne?

Research data for pediatric populations across all indications remain limited according to official summaries. For the elderly, official guidance notes that treatment should begin cautiously, which is a consideration of potential differences in how the drug is cleared by the body.


Q: Does this medicine interact with herbal supplements like St. John's Wort?

Official interaction guidance lists a general caution regarding the use of herbal supplements. Some agents, like St. John’s Wort, are known to potentially affect the liver enzymes that metabolize this type of medicine, which could change the concentration of Half Beta-Prograne in the bloodstream.


Q: What are the common early side effects when starting Half Beta-Prograne?

Official safety data categorize adverse effects by frequency. Common reactions include fatigue, cold extremities, and sleep disturbances. These effects, particularly fatigue and lassitude (a feeling of weariness), are often noted in regulatory summaries as transient, meaning they may be more noticeable upon treatment initiation but tend to lessen over time.

How should Half Beta-Prograne be stored and disposed of?

How to Store and Dispose of Half Beta-Prograne

Official regulatory labeling dictates strict conditions for the storage and disposal of Half Beta-Prograne (Propranolol Hydrochloride).

Storage Requirements

This medicine must be stored in its original package and must not be stored above 25 C (77 F). The product must be protected from light, moisture, freezing, and excessive heat. For safety, it is a mandatory requirement that Half Beta-Prograne be stored out of the sight and reach of children.

Disposal Instructions

Official regulatory documents state that there are no special requirements for the disposal of this product. Unused or expired medication must be discarded according to local requirements, which often involves consulting a pharmacist or local waste disposal service for guidance on approved procedures for medicinal product waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Half Beta-Prograne found in:

A-Z Index: